Tetrahedral, Inc. is a biotech company focused on innovative approaches to cancer and longevity treatments. Founded in 2024, the company leverages research inspired by Raymond Damadian and Gilbert Ling, reviving scientific concepts that have been overlooked. Tetrahedral's work revolves around targeting intracellular water dynamics to impact cellular processes, particularly in cancer treatment. The company is backed by Long Journey Ventures and the 1517 Fund, having secured pre-seed funding as part of the inaugural Flux Capacitor cohort.